{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:27:57Z","timestamp":1762928877382},"reference-count":14,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          Sepsis und Multiorganversagen\u2002Die Rolle der therapeutischen Plasmapherese (TP) in der Therapie der Sepsis mit Multiorganversagen ist noch nicht abschlie\u00dfend gekl\u00e4rt (Kategorie III der American Society for Apheresis, ASFA). Zwar zeigen die verf\u00fcgbaren randomisiert kontrollierten Studien (RCT) keinen eindeutigen \u00dcberlebensvorteil, prospektive Daten von 2018 belegen jedoch ein gutes Sicherheitsprofil und eine g\u00fcnstige Beeinflussung von Surrogatparametern auch bei hoch Katecholamin-pflichtigen Patienten im septischen Schock.<\/jats:p><jats:p>\n          Akutes Leberversagen\u2002Eine multizentrische RCT von 2016 konnte einen signifikanten \u00dcberlebensvorteil durch die Durchf\u00fchrung von \u201eHigh Volume\u201c-TP bei Patienten im akuten Leberversagen zeigen. Dies galt allerdings nur in der Subgruppe der nicht transplantierten Patienten.<\/jats:p><jats:p>\n          Katastrophales Antiphospholipid-Antik\u00f6rper-Syndrom (CAPS) Retrospektive Datenauswertungen von 2016 zeigten einen deutlichen \u00dcberlebensvorteil einer 3-Fachtherapie, welche die TP beinhaltet. Dies veranlasste die ASFA in ihren neuen, 2019 erschienenen Leitlinien das CAPS erstmals in die ASFA-Kategorie I einzustufen.<\/jats:p><jats:p>\n          Thyreotoxische Krise\u2002Retrospektive Analysen von 2018 ergaben eine effektive Elimination von Schilddr\u00fcsenhormonen durch die TP. Aufgrund dessen erkennt die ASFA in ihren neuen Leitlinien die TP als Zweitlinientherapie der thyreotoxischen Krise an.<\/jats:p>","DOI":"10.1055\/a-1340-3256","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T23:31:34Z","timestamp":1611963094000},"page":"167-170","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutische Plasmapherese in der Intensivmedizin"],"prefix":"10.1055","volume":"146","author":[{"given":"Andreas","family":"Goldschmied","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Kardiologie und Angiologie, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reimer","family":"Riessen","sequence":"additional","affiliation":[{"name":"Internistische Intensivstation, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice \u2013 Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue","volume":"34","author":"A Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13054-020-2799-5","article-title":"Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock","volume":"24","author":"K Stahl","year":"2020","journal-title":"Crit Care"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s13054-014-0699-2","article-title":"The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis","volume":"18","author":"E Rimmer","year":"2014","journal-title":"Crit Care"},{"key":"ref4","first-page":"14","article-title":"To remove and replace-a role for plasma exchange in counterbalancing the host response in sepsis","volume":"23","author":"S David","year":"2019","journal-title":"Crit\u00a0Care"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13054-018-2220-9","article-title":"Early therapeutic plasm\na exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers","volume":"22","author":"H Knaup","year":"2018","journal-title":"Crit Care"},{"key":"ref6","first-page":"1323","article-title":"Randomized controlled study of plasma exchange combined with molecular adsorbent re-circulating system for the treatment of liver failure complicated with hepatic encephalopathy","volume":"59","author":"Y K Huang","year":"2012","journal-title":"Hepatogastroenterology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2015.08.018","article-title":"High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial","volume":"64","author":"F S Larsen","year":"2016","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jca.21737","article-title":"Therapeutic plasma exchange in acute liver failure","volume":"34","author":"K Stahl","year":"2019","journal-title":"J Clin Apher"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jca.21799","article-title":"Therapeutic plasma exchange in acute on chronic liver failure","volume":"35","author":"K Stahl","year":"2020","journal-title":"J Clin Apher"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3748\/wjg.v26.i2.219","article-title":"Plasma exchange in patients with acute and acute-on-chronic liver failure: A systematic review","volume":"26","author":"E X Tan","year":"2020","journal-title":"World J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","author":"K Legault","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500\u00a0patients from the International CAPS Registry","volume":"15","author":"I Rodr\u00edguez-Pint\u00f3","year":"2016","journal-title":"Autoimmun Rev"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2796.2008.01942.x","article-title":"Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement","volume":"264","author":"P Marson","year":"2008","journal-title":"J Intern Med"},{"key":"ref14","first-page":"4135940","article-title":"Severe Hyperthyroidism Complicated by Agranulocytosis Treated with Therapeutic Plasma Exchange: Case Report and Review of the Literature","volume":"2018","author":"V Garla","year":"2018","journal-title":"Case Rep Endocrinol"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1340-3256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T23:32:30Z","timestamp":1611963150000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1340-3256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":14,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2021,1,29]]},"published-print":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1340-3256","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]}}}